Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Martin Robinson, Nicholas J Slevin, Peter Hoskin, Kevin J. Harrington, David L Morgan, Christopher Gaffney
Publikováno v:
Journal of Clinical Oncology. 27:5751-5756
Purpose To evaluate the effect of epoetin alfa on local disease-free survival (DFS), overall survival (OS), and cancer treatment–related anemia and fatigue in patients with head and neck cancer receiving radical radiotherapy with curative intent. P
Autor:
Dimitry Serge Antoine Nuyten, Zelanna Goldberg, Nancy Y. Lee, Margarida Geraldes, J. Thaddeus Beck, Robert I. Haddad, Kevin J. Harrington, Ezra E.W. Cohen, Makoto Tahara, Robert L. Ferris, Jean Bourhis
Publikováno v:
Journal of Clinical Oncology. 35:TPS6093-TPS6093
TPS6093 Background: Cisplatin + radiotherapy is a standard-of-care treatment for patients (pts) with LA SCCHN. Combining avelumab (fully human IgG1 anti–PD-L1 antibody) and CRT may synergistically activate multiple immune-mediated mechanisms to eff
Autor:
Lorna Grove, James Spicer, Sally Ellis, Sola Adeleke, Martin Forster, Jennifer Laude, Simon Smith, Glen Clack, Z. Viney, Kevin J. Harrington, Lyndall McLellan, George Lazaridis, Magnus T. Dillon
Publikováno v:
Journal of Clinical Oncology. 34:TPS2603-TPS2603
Tumour control rates from radiation therapy (RT) are limited by normal tissue toxicities. Novel strategies are required to selectively sensitize tumour cells to radiation-induced DNA damage. The G2 cell cycle checkpoint is an attractive target for th
Autor:
Petra Holečková, Georgy M. Manikhas, Iman El-Hariry, Natalie Franklin, Sergio Santillana, Hisham Mehanna, Paul Wissel, Minish Mahendra Jain, Geza Horvai, Stéphane Temam, Thelma Netherway, Jean Bourhis, Nigel Biswas-Baldwin, Ida D'Onofrio, Yan Sun, Stefan Dietzsch, Pavol Dubinsky, Philippe Legenne, Kevin J. Harrington, Anil K. D'Cruz
Publikováno v:
ResearcherID
6005 Background: Epidermal growth factor receptor (EGFR) and ErbB2 are overexpressed in up to 90% and 40% of SCCHN, respectively. L, a tyrosine kinase inhibitor (TKI) of both EGFR and ErbB2, demonstrates tumor responses in SCCHN. Methods: Patients wi
Autor:
F. Adab, B. K. Yap, M. S. Rogers, Roger A'Hern, M. Sydenham, Emma Hall, Christopher M. Nutting, S. Jefferies, Kevin J. Harrington, C. Scrase
Publikováno v:
Journal of Clinical Oncology. 27:LBA6006-LBA6006
LBA6006 Background: Xerostomia is the most common late toxicity of RT to the head and neck. IMRT dose distributions reduce the dose delivered to parotid gland. PARSPORT investigated the role of IMRT in reducing xerostomia in patients with head and ne